CA2902144C - Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate - Google Patents

Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate Download PDF

Info

Publication number
CA2902144C
CA2902144C CA2902144A CA2902144A CA2902144C CA 2902144 C CA2902144 C CA 2902144C CA 2902144 A CA2902144 A CA 2902144A CA 2902144 A CA2902144 A CA 2902144A CA 2902144 C CA2902144 C CA 2902144C
Authority
CA
Canada
Prior art keywords
cancer
use according
targeted
cto
chemotherapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2902144A
Other languages
English (en)
French (fr)
Other versions
CA2902144A1 (en
Inventor
Rashida A. Karmali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactical Therapeutics Inc
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Publication of CA2902144A1 publication Critical patent/CA2902144A1/en
Application granted granted Critical
Publication of CA2902144C publication Critical patent/CA2902144C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2902144A 2013-04-01 2014-03-28 Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate Active CA2902144C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/986,103 US9089570B2 (en) 2010-09-03 2013-04-01 Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US13/986,103 2013-04-01
PCT/US2014/032253 WO2014165412A2 (en) 2013-04-01 2014-03-28 Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate

Publications (2)

Publication Number Publication Date
CA2902144A1 CA2902144A1 (en) 2014-10-09
CA2902144C true CA2902144C (en) 2021-02-09

Family

ID=51621074

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2902144A Active CA2902144C (en) 2013-04-01 2014-03-28 Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate

Country Status (10)

Country Link
US (1) US9089570B2 (https=)
EP (1) EP2981169B1 (https=)
JP (1) JP6410795B2 (https=)
KR (2) KR20210019116A (https=)
CN (1) CN105120663B (https=)
AU (1) AU2014248377B2 (https=)
CA (1) CA2902144C (https=)
IL (1) IL241827B (https=)
WO (1) WO2014165412A2 (https=)
ZA (1) ZA201506037B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186640B2 (en) * 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN107890467A (zh) * 2017-11-24 2018-04-10 中国医学科学院基础医学研究所 干扰能量代谢的药物在胰腺癌复发中的应用
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate
WO2024208247A1 (zh) * 2023-04-04 2024-10-10 广东银珠医药科技有限公司 羧胺三唑在制备治疗肿瘤骨转移的药物中的用途
WO2024235217A1 (zh) * 2023-05-15 2024-11-21 广东银珠医药科技有限公司 一种抗肺癌联合用药物及其应用
CN119971050A (zh) * 2023-11-10 2025-05-13 广东银珠医药科技有限公司 羧胺三唑与化疗药的组合物及联用治疗实体瘤的用途
CN120817906A (zh) * 2024-04-12 2025-10-21 广东银珠医药科技有限公司 一种三氮唑类化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575902C (en) * 1995-07-21 2010-06-08 Tactical Therapeutics Inc Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide
US5728707A (en) 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
CN101801983B (zh) * 2007-08-13 2014-01-29 辛塔制药公司 调控hsp90活性的三唑化合物
CN101669941B (zh) * 2008-09-09 2012-11-07 中国医学科学院基础医学研究所 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
MX2012002730A (es) * 2009-09-04 2012-07-20 Tactical Therapeutics Inc Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato.
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Also Published As

Publication number Publication date
EP2981169A2 (en) 2016-02-10
EP2981169A4 (en) 2016-09-14
WO2014165412A3 (en) 2015-01-29
JP2016515619A (ja) 2016-05-30
AU2014248377B2 (en) 2018-02-01
AU2014248377A1 (en) 2015-09-03
IL241827B (en) 2019-02-28
KR20210019116A (ko) 2021-02-19
KR20160026824A (ko) 2016-03-09
US9089570B2 (en) 2015-07-28
US20140294806A1 (en) 2014-10-02
ZA201506037B (en) 2021-09-29
JP6410795B2 (ja) 2018-10-24
CA2902144A1 (en) 2014-10-09
CN105120663A (zh) 2015-12-02
WO2014165412A2 (en) 2014-10-09
HK1214921A1 (zh) 2016-08-12
EP2981169B1 (en) 2021-05-05
CN105120663B (zh) 2017-08-04

Similar Documents

Publication Publication Date Title
CA2902144C (en) Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
Majeed et al. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
Park et al. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib
JP6784668B2 (ja) 相乗的オーリスタチン組合せ
KR102456088B1 (ko) 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
AU2023249277A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
Quick et al. Current therapeutic paradigms in glioblastoma
AU2009210656A1 (en) Use of picoplatin and cetuximab to treat colorectal cancer
Kimple et al. Radiosensitization of epidermal growth factor receptor/HER2–positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
Figlin et al. NCCN Task Force Report: mTOR inhibition in solid tumors
JP2026506429A (ja) Ｍｔａ協同的ｐｒｍｔ５阻害薬を使用した癌治療
Canu et al. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo
Vansteenkiste et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model
WO2010132596A1 (en) Use of picoplatin to treat colorectal cancer
US20160367553A1 (en) Methods and Compositions for Treating Cancers having Acquired Resitance to prior Chemotherapeutic and Targeted Drugs Using Carboxyamidotriazole Orotate
JP2025505705A (ja) がんの処置における使用のためのＩＧＦ１Ｒ阻害剤及びＡｋｔ阻害剤
Huang et al. Molecular targeting of growth factor receptor signaling in radiation oncology
HK1214921B (en) Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
Pivot et al. Combining molecular targeted therapies: clinical experience
Jemel et al. The offer of chemistry to targeted therapy in cancer
Bironzo et al. , Achievements in Targeted Therapies-ERS Monographs-Lung Cancer
Tubby et al. American Society of Clinical Oncology (ASCO) 48th Annual Meeting 2012, Chicago, Illinois, USA-June 1-5, 2012
Karapanagiotou et al. Second-line chemotherapy for non-small-cell lung cancer
Johnson New antiangiogenic compounds and strategies for their clinical development

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190122

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - SMALL

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321